Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Impact · against what's priced in

The announcement of a lead plaintiff deadline for a securities fraud class action is a marginal negative for Aardvark Therapeutics. While the clinical failure and FDA hold are already reflected in the stock's collapse, the lawsuit introduces a potential future cash liability.

AARD−0.20

No priced-in read yet